茄子种子多糖化物水解剂 改善硫酸德克斯 通过调节肠道微生物群来诱导性结肠炎
Kangjia Jiang1, Duo Wang1, Le Su1
1State Key Laboratory of Biobased Material and Green Papermaking, School of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan 250353, China.
Pharmaceuticals (Basel, Switzerland)
|August 26, 2023
概括
茄子种子多糖化水解剂 (TSPH) 通过恢复肠道微生物群和调节代谢物,减少大肠炎小鼠的结肠炎症. 这表明TSPH是TSPH.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 涉及慢性结肠炎症,通常用具有风险的免疫抑制剂治疗.
- 植物衍生型多糖体对生物活性,包括抗炎作用有很大的前景.
- 茄子种子多糖化水解剂 (TSPH) 正在被探索其潜在的治疗益处.
研究的目的:
- 在性结肠炎 (UC) 的小鼠模型中研究种子多糖化水解盐 (TSPH) 的抗炎作用.
主要方法:
- TSPH是通过三酸水解茄种子多糖 (TSP) 来制备的.
- 使用UV,TLC,FT-IR和HPLC-ESI/MS分析了TSPH的结构和特性.
- 评估了TSPH的效果在硫酸 (DSS) 诱导的大肠炎小鼠.
主要成果:
- 在UC小鼠中,TSPH治疗改善了结肠病理性病变,并降低了UC小鼠的炎症性细胞因子水平.
- TSPH增加了结肠紧结蛋白的表达.
- TSPH调节了肠道微生物群的组成,丰富了像Prevotella和Blautia这样的有益细菌,其中Blautia与酸正相关.
结论:
- 在结肠炎中,TSPH有效抑制结肠炎症并恢复肠道微生物群平衡.
- TSPH调节细菌代谢物,表明其作为大肠炎管理的功能性食物的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Inflammatory Bowel Disease I: Ulcerative Colitis
215
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
215
Drugs for Treatment of Diarrhea-Predominant IBS
212
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
212
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
465
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
465
Drugs for Treatment of Constipation-Predominant IBS
206
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
206


